Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use
- None.
- None.
Insights
The re-acquisition of exclusive worldwide rights by Autonomix Medical, Inc. to its technology in the cardiology field represents a strategic consolidation of its intellectual property, which could have significant implications for its market positioning and future revenue streams. From a market research perspective, this move could potentially open up new market segments for Autonomix, allowing it to directly compete in the cardiology diagnostics and treatment space, which is a high-value sector with growing demand due to the global burden of cardiovascular diseases.
Moreover, the timing of this re-acquisition aligns with Autonomix's recent initial public offering (IPO), suggesting a calculated effort to enhance shareholder value by expanding the company's portfolio and strategic flexibility. The lockup agreement associated with the warrant issuance serves as a stabilizing factor for the stock price in the short term, potentially reducing sell-side pressure post-IPO. However, investors should be aware of the dilutive effect of the additional 1,600,000 shares once the lockup period expires.
From a medical research standpoint, Autonomix's catheter-based sensing technology addresses significant unmet needs in the management of pain associated with diseases, particularly in cardiology and oncology. The ability to sense neural signals and target nerves for treatment presents a novel approach that could offer advantages over systemic drugs and blind treatment methods. The precision of this technology could lead to improved patient outcomes and reduced side effects, which is particularly relevant in the context of the opioid crisis and the need for alternative pain management solutions.
The company's focus on a pancreatic cancer pain development program and the upcoming first-in-human clinical study are critical milestones. Success in these studies could validate the technology's efficacy and safety, potentially accelerating regulatory approvals and adoption in clinical practice. This could ultimately translate into a competitive edge for Autonomix in a market where innovation is highly valued.
Analyzing the financial implications of Autonomix's re-acquisition of rights, the non-cash warrant arrangement is a strategic financial decision that minimizes immediate cash outlay while incentivizing Impulse Medical, Inc. with an equity stake. The fixed value of $8 million for the warrant, divided by the IPO price, reflects a forward-looking valuation of the technology's potential in the cardiology field. This arrangement could be seen as a vote of confidence in Autonomix's future, but it also indicates a need for careful monitoring of share price fluctuations and potential dilution effects.
Investors should consider the long-term revenue potential of the cardiology and pancreatic cancer pain applications against the costs associated with preclinical and clinical development. The company's progress in preclinical development and the strategic expansion into the cardiology sector suggest a trajectory for growth, but the inherent risks of clinical development and the need for substantial capital investment to bring these technologies to market remain significant considerations.
Autonomix now wholly owns development and commercialization rights to its technology in all indications
Re-acquisition broadens Autonomix’s development and strategic opportunities
THE WOODLANDS, TX, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has regained exclusive worldwide rights to its technology for cardiology field use from Impulse Medical, Inc.
In December 2021, Autonomix granted Impulse Medical, Inc., a license to its technology for use in the field of cardiology. In July 2023, the Company entered into a termination agreement for the license agreement in exchange for the issuance, upon the closing of its initial public offering, of a non-cash warrant to purchase the number of shares of common stock based upon a fixed value of
“We have made significant progress over the course of the past year. With the recent closing of our IPO and listing onto Nasdaq as well as the progress we’ve made on the preclinical development front, we continue to build momentum. Regaining the cardiology rights to our innovative technology broadens our development opportunities and provides further optionality related to our development strategy moving forward. Looking ahead, we remain focused on our pancreatic cancer pain development program and are on track to commence our first-in-human clinical study this quarter,” commented Lori Bisson, Chief Executive Officer of Autonomix.
The Company’s catheter-based sensing technology is being developed to do two things: sense neural signals associated with pain or disease and precisely target those nerves for treatment. Autonomix believes this technology is a better alternative to the current approaches commonly used today, where doctors either rely on systemic drugs like opioids that lose effectiveness and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body.
For more information about the Company’s technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and need an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’
Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the final offering statement filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com
FAQ
What technology did Autonomix regain exclusive worldwide rights to?
How many shares of common stock can be purchased through the non-cash warrant?
What is the exercise price per share for the non-cash warrant?
What is Autonomix's focus for development?
